Molecular Targeted α-Particle Therapy for Oncologic Applications
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: A significant challenge facing traditional cancer therapies is their propensity to significantly harm normal tissue. The recent clinical success of targeting therapies by attaching them to antibodies that are specific to tumor-restricted biomarkers marks a new era of cancer treatments. CONCLUSION: In this article, we highlight the recent developments in α-particle therapy that have enabled investigators to exploit this highly potent form of therapy by targeting tumor-restricted molecular biomarkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834 · cited 2×
“Although mertansine alone causes the expected severe adverse effects of a chemotherapeutic agent, conjugating it to tumor-targeting antibodies results in a significantly higher intratumoral concentration compared with normal tissue and thus dramatically increases the therapeutic window [11].”
BackgroundAlpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408
Tumor therapy with targeted atomic nanogenerators.
McDevitt, M. R., Ma, D., Lai, L. T., Simon, J., Borchardt, P., Frank, R. K., Wu, K., Pellegrini, V., Curcio, M. J., Miederer, M., et al. (2001) · Science · doi:10.1126/science.1064126 · Cited by 501
Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis
Almutairi, A., Rossin, R., Shokeen, M., Hagooly, A., Ananth, A., Capoccia, B., Guillaudeu, S., Abendschein, D., Anderson, C. J., Welch, M. J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811757106 · Cited by 235
Design and synthesis of 225Ac radioimmunopharmaceuticals.
McDevitt, M. R., Ma, D., Simon, J., Frank, R. K., & Scheinberg, D. A. (2002) · Applied Radiation and Isotopes · doi:10.1016/s0969-8043(02)00167-7 · Cited by 225
Production of Ac-225 from Th-229 for Targeted α Therapy
Apostolidis, C., Molinet, R., Rasmussen, G., & Morgenstern, A. (2005) · Analytical Chemistry · doi:10.1021/ac0580114 · Cited by 215 · cited 1×
“Actinium-225 has a half-life of 10 days and is produced as a decay product of uranium [67, 68].”
BackgroundMiederer, M., Scheinberg, D. A., & McDevitt, M. R. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.009 · Cited by 210
Apostolidis, C., Molinet, R., McGinley, J., Abbas, K., Möllenbeck, J., & Morgenstern, A. (2005) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2004.06.013 · Cited by 176 · cited 1×
“In addition to purifying from a uranium source, some investigators have developed a method of producing small amounts of high purity 225Ac from a standard proton-beam cyclotron using very long irradiation times (7–50 hours) [69].”
BackgroundProduction of actinium-225 for alpha particle mediated radioimmunotherapy.
Boll, R. A., Malkemus, D., & Mirzadeh, S. (2005) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2004.12.003 · Cited by 171
Cited by
Radioactive Main Group and Rare Earth Metals for Imaging and Therapy
Kostelnik, T. I., & Orvig, C. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00294 · Cited by 483
Development of targeted alpha particle therapy for solid tumors.
Tafreshi, N. K., Doligalski, M. L., Tichacek, C. J., Pandya, D. N., Budzevich, M. M., El-Haddad, G., Khushalani, N. I., Moros, E. G., McLaughlin, M. L., Wadas, T. J., et al. (2019) · Molecules · doi:10.3390/molecules24234314 · Cited by 157
Self-citationAliphatic polyesters for medical imaging and theranostic applications
Nottelet, B., Darcos, V., & Coudane, J. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.06.023 · Cited by 68
Shi, M., Jakobsson, V., Greifenstein, L., Khong, P.-L., Chen, X., Baum, R. P., & Zhang, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1034315 · Cited by 68
The Added Value of Diagnostic and Theranostic PET Imaging for the Treatment of CNS Tumors
Pruis, I. J., van Dongen, G. A. M. S., & Veldhuijzen van Zanten, S. E. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031029 · Cited by 35
“Of these, alpha-emitting radionuclides have significantly higher relative biological effectiveness compared to beta-emitting radionuclides [12].”
Background
Metadata
- Authors
- Wadas, T. J., Pandya, D. N., Solingapuram Sai, K. K., & Mintz, A.
- Venue
- American Journal of Roentgenology
- Publisher
- American Roentgen Ray Society
- Published
- 2014-08
- Volume
- 203
- Issue
- 2
- Pages
- 253-260
- ISSN
- 0002-9580 (ISSN-L)
- 0361-803X
- 1546-3141
- OpenAlex
- W2010233571
- Cited by
- 65
- References
- 9
- FWCI
- 4.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.